Background. Candidemia is a common healthcare-associated bloodstream infection associated with high morbidity and mortality. No current estimates exist for understanding its burden in the United States.
Methods. In 2017, CDC's Emerging Infections Program (EIP) performed laboratory-and active population-based candidemia surveillance in 45 counties in nine states (California, Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, Tennessee) , encompassing ~17 million persons. A case was defined as Candida species isolated from blood in a surveillance area resident. EIP site staff reviewed medical records to collect demographic and clinical data. Using 2016 US census data, we created weighted estimates of national and regional incidence rates and mortality in persons with candidemia (defined as death from any cause within 7 days of incident candidemia).
Results. A total of 1,226 candidemia cases were identified in 2017. We estimated 23,000 candidemia cases (95% CI 20,000-25,000) occurred in the United States in 2017. Overall estimated incidence was 7.0/100,000 persons, with elevated rates in adults ≥65 years (20.3/100,000), males (8.0/100,000), and people of Black race (12.6/100,000) (table). Incidence was highest in the South Atlantic region (8.0/100,000) and lowest in the Pacific (6.0/100,000). Estimated number of deaths was 3,000 (1,000-5,000).
Conclusion. Our analysis highlights the substantial burden of candidemia in the US Because candidemia is only one form of invasive candidiasis, the true burden of invasive infections due to Candida species is likely higher. Ongoing surveillance can support future burden estimates and help assess the impact of prevention interventions.
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No reported disclosures. Methods. NYS hospital blastomycosis discharge codes from the January 2007-December 2016 Statewide Planning and Research Cooperative System dataset were reviewed. To better understand illness in the area of highest incidence, NYSDOH contacted CD physicians to identify patients diagnosed with blastomycosis during April 2016-February 2018. Chart reviews and interviews were conducted to obtain travel and disease progression details.
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Results. During 2007-2016, there were 279 blastomycosis diagnoses in NYS. Mean annual blastomycosis diagnoses during 2007-2015 was 24 (incidence: 0.1/100,000 persons); in 2016, there were 59 blastomycosis diagnoses (incidence: 0.3/100,000 persons). A CD county had the highest state incidence, with a rate increase from 2.0/100,000 persons during 2007-2015 to 4.1/100,000 persons during 2016. CD physicians provided contact and clinical information for the six initially-identified patients and two additional patients seen during April 2016-February 2018. All experienced delays in diagnosis, seven lacked travel history, two had cutaneous blastomycosis, three had pulmonary blastomycosis, and three had disseminated blastomycosis. One died from blastomycosis and another required long-term ventilator support. Seven cases were identified by culture or histopathology; the diagnostic method for one was unknown.
Conclusion. One CD county had blastomycosis rates similar to known endemic areas; patients lacked travel history to endemic areas, indicating locally acquired blastomycosis might have occurred. To improve prompt diagnosis, NYS clinicians and laboratorians should consider blastomycosis in patients with pneumonia, even without travel history to endemic areas. Further evaluation is needed to determine whether the endemic area of NYS has expanded.
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